Targeting CLDN18.2 with Zolbetuximab Prolongs Survival When Combined with mFOLFOX6 in CLDN18.2-positive, HER2-negative Advanced Gastric or Gastro-Oesophageal Junction Cancer
Findings from the SPOTLIGHT study
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1552 results
RANO and Modified RANO Criteria Demonstrate Similar Correlations Between PFS and OS in Patients with Newly Diagnosed and Recurrent Glioblastoma
More complex imaging criteria to assess treatment response in neuro-oncology do not improve the predictive value of the original RANO criteria
Implementation of Door-to-Door HPV-based Cervix Screening Results in Better Attendance of Follow-Up Treatment Compared to Community Health Days
Findings from the ASPIRE Mayuge, cluster-randomised study
No Clinical Benefit from Nivolumab Plus Ipilimumab Over Nivolumab Alone as First-Line Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck
Findings from the CheckMate 714 study
GD2-CART01 May Induce Sustained Antitumour Effect in a Proportion of Patients with Relapsed or Refractory Neuroblastoma
Findings from a phase I/II study
Concurrent Intrathecal and Intravenous Nivolumab is Safe and Feasible with Preliminary Evidence of Clinical Benefit in Patients with Melanoma and Leptomeningeal Disease
Findings from an interim analysis of the first-in-human phase I/Ib study
FDA Grants Accelerated Approval to Enfortumab Vedotin-ejfv with Pembrolizumab for Locally Advanced or Metastatic Urothelial Carcinoma
Evidence for efficacy is based on the results from the EV-103/KEYNOTE-869 study
Safety, Tolerability and Antitumour Activity of Lorlatinib in Patients with ALK-Driven Refractory or Relapsed Neuroblastoma
Findings from the NANT2015-02 study
EMA Recommends Granting a Paediatric-Use Marketing Authorisation for Sodium Thiosulfate
It is indicated for the prevention of ototoxicity induced by cisplatin in paediatric patients with localised, non-metastatic, solid tumours
Combination of Enzalutamide Plus Abiraterone Acetate and Prednisone Offers No Clinical Advantage Over Enzalutamide Alone in First-Line Treatment of mCRPC
Findings from the Alliance A031201 study
Isolated Hepatic Perfusion with Melphalan Improves Response Rate and PFS in Previously Untreated Patients with Isolated Liver Metastases from Uveal Melanoma
Findings from the SCANDIUM study
EMA Recommends Extension of Therapeutic Indications for Lisocabtagene Maraleucel
New indication concerns treatment of adult patients with DLBCL, HGBCL, PMBCL and FL3B, who relapsed within 12 months from completion of, or are refractory to, first-line chemoimmunotherapy